4
Views
12
CrossRef citations to date
0
Altmetric
Original Article

Penicillamine in Rheumatoid Arthritis: Clinical Pharmacology and Biochemical Properties

Pages 58-63 | Published online: 12 Jul 2009

References

  • Bacon P. A., Tribe C. R., MacKenzie J. C., et al. Penicillamine nephropathy in rheumatoid arthritis. A clinical, pathological and immunological study. Quart J Med 1976; 45: 661
  • Benveniste M., Crouzet J., Homberg J. C., et al. Pemphigus induced by D‐penicillamine during treatment of rheumatoid arthritis. Nouv Presse Med 1975; 4: 3115
  • Bucknall R. C., Dixon A. St. J., Glieb E. N. Myasthenia gravis associated with penicillamine treatment for rheumatoid arthritis. BMJ 1975; 1: 600
  • Camus J. P., Jaffe I. A., Crouzet A., et al. Pyrithioxine, original treatment for rheumatoid arthritis. Initial study of 72 cases with review at 6 months. Rev Rhum 1978; 45: 95
  • Crouzet J., Camus J. P., Lecca A. P., et al. Lupus induced by D‐penicillamine during the treatment of rheumatiod arthritis. Ann Med Intern 1974; 125: 71
  • Day A. T., Golding J. R., Lee P. N., et al. Penicillamine in rheumatoid disease: a long term study. BMJ 1974; 1: 180
  • Fakhiuddin A., Sumalnop V., Spain D. M., et al. Thrombohemolytic thrombocytopenic purpura during penicillamine therapy. Arch Intern Med 1978; 138: 1292
  • Harrison E. E., Hickman J. W. Hemolytic anemia and thrombocytopenia associated with penicillamine ingestion. South Med 1975; 568: 113
  • Henkin R. I., Bradley D. F. Regulation of taste acuity by thiols and metal ions. Proc Natl Acad Sci USA 1969; 62: 30
  • Huskisson E. C., Dieppe P. A., Scott J., et al. Immunostimulant therapy with levamisole for rheumatoid arthritis. Lancet 1976; 1: 393
  • Huskisson E. C., Jaffe I. A., Scott J., et al. 5‐Thiopyridoxine in rheumatoid arthritis. I. Clinical Studies
  • Jaffe I. A. The effect of penicillamine and mercaptopyridoxine in rheumatoid arthritis. Abstr. 243, Fifth European Congress on Rheumatic Diseases, Stockholm, 1963
  • Jaffe I. A. Rheumatoid arthritis with arteritis. Report of a case treated with penicillamine. Ann Intern Med 1964; 61: 556
  • Jaffe I. A. D‐Penicillamine. Bull Rheum Dis 1977–78; 28: 948
  • Jaffe I. A., Altman K., Merryman P. The anti‐pyridoxine effect of penicillamine in man. J Clin Invest 1964; 43: 1869
  • Jaffe I. A., Huskisson E. C., Merryman P., et al. 5‐Thiopyridoxine in Rheumatoid Arthritis. II. Experimental Studies
  • Jaffe I. A., Merryman P. Effect of increased serum sulfhydryl content on titer of rheumatoid factor. Ann Rheum Dis 1968; 27: 14
  • Kagan W. A., Ascensao J. A., Pahwa R., et al. Aplastic anemia: presence in human bone marrow of cells that suppress myelopoesis. Proc Natl Acad Sci USA 1976; 73: 2890
  • Leca A. P., Camus J. P. Ankylosing spondylitis: treatment failures with D‐penicillamine. Nouv Presse Med 1975; 4: 112
  • Liyange S. P., Currey H. L. Failure of oral D‐penicillamine to modify adjuvant arthritis or immune response in the rat. Ann Rheum Dis 1972; 31: 521
  • Masters C. L., Dawkins R. L., Zilko P., et al. Penicillamine‐associated myasthenia gravis. Antiacetylcholine receptor and antistriational antibodies. Am J Med 1977; 63: 689
  • May V., Aristoff H., Lecoq G. Syndrome of Gougerot‐Sjögren induced by D‐penicillamine. Rev. Rhum 1977; 44: 497
  • Multi‐Centre Trial Group. Controlled trial of (D)‐penicillamine in severe rheumatoid arthritis. Lancet 1973; 1: 275
  • Nimni M. E., Bavetta L. A. Collagen defect induced by penicillamine. Science 1965; 150: 905
  • Schrader P. L., Peters H. A., Dahl D. S. Polymyositis and penicillamine. Arch Neurol 1972; 27: 456
  • Sternlieb I., Bennett B., Scheinberg I. H. D Penicillamine induced Goodpasture's syndrome in Wilson's disease. Ann Intern Med 1975; 82: 673
  • Tabachnik M., Eisen H. N., Levine B. New mixed disulfide: penicillamine‐cysteine. Nature 1954; 174: 701
  • Von Wilhelm F. K., Nowak H. Zur Vitamin B6‐und Antivitamin B6‐Wirksamheit von Pyridoxal‐De‐rivaten unter besonderer Berücksichtigung des Pyrithioxins. Arzneim‐Forsch 1967; 17: 572
  • Walshe J. M. Penicillamine: a new oral therapy for Wilson's disease. Quart J Med 1956; 21: 487

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.